Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 10/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MPI | P34949 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2766069 | 0.84 | HTR1A (0.71) | HTR1AALDH1A1KMT2AKDM4ELMNA | |
| SCHEMBL17549635 | 0.83 | ALDH1A1 (0.79) | HTR1AALDH1A1KMT2AKDM4ELMNA | |
| SCHEMBL2767637 | 0.80 | HTR1A (0.54) | HTR1AALDH1A1KMT2AMAPT | |
| SCHEMBL2765916 | 0.79 | DRD2 (0.53) | HTR1AALDH1A1KMT2ALMNATSHR | |
| SCHEMBL16026463 | 0.78 | KMT2A (0.83) | HTR1AALDH1A1KMT2AGFERMAPT | |
| Hydrochloric Acid SCHEMBL7934846 | 0.77 | KMT2A (0.83) | HTR1AALDH1A1KMT2ALMNAGFER | |
| SCHEMBL351997 | 0.76 | HTR1A (0.81) | HTR1AALDH1A1KMT2AGFERMAPT | |
| SCHEMBL6357616 | 0.73 | HTR1A (0.70) | HTR1AALDH1A1KMT2AKDM4ELMNA | |
| SCHEMBL2768505 | 0.73 | KMT2A (0.71) | ALDH1A1KMT2ALMNATSHRL3MBTL1 | |
| SCHEMBL9412135 | 0.73 | HTR1A (0.58) | HTR1AALDH1A1KMT2AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1627871-B1 | CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-7449466-B2 | Cyclic aminophenyl sulfamate derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-20060189625-A1 | Cyclic aminophenyl sulfamate derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| EP-1627871-A1 | CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE | Teikoku Hormone Mfg. Co., Ltd. (JP) | 2006-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189625-A1 | Cyclic aminophenyl sulfamate derivative | SHBG, STS, ARSA | HTR1A 2511/4885ALDH1A1 2953/4885KMT2A 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.